AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$TMO

Pettiti Gianluca sold $2.5M of TMO

Pettiti Gianluca (President & COO) sold 4,133 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $614.38 ($2.54M total) across 2 trades on 2026-08-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pettiti Gianluca
Published Sep 1, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TMO
Bearish
medium confidence
Mentioned
$TMO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMOBearishLow
01

Why it matters

The filing provides the first public record of the insider's sale, offering a data point for monitoring executive sentiment.

02

Market read

While the transaction is modest, it adds to the ongoing assessment of insider activity at a large cap biotech supplier.

03

What to watch

The 10b5‑1 plan may have been set months ago, reducing the informational value of the trade.

Relevance 5/10Novelty 6/10Timing: post‑market filing on Sep 1 2026

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$TMOBearishMedium confidence
Context

President & COO Gianluca Pettiti sold 4,133 shares for $2.5M via a 10b5‑1 plan.

Expected impact

Potential short‑term pressure on TMO stock, modest downside of 1‑2%.

Evidence & confidence

The sale size is modest relative to market cap, but the insider is a senior officer and used a pre‑arranged plan, suggesting a neutral to slightly bearish signal.

Market effects

Sector

Minimal impact on the life‑science equipment sector.

Regional

No notable regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Company
    Thermo Fisher Scientific Inc.

    Global provider of scientific instruments and services.

  • Executive
    Gianluca Pettiti

    President & COO of Thermo Fisher Scientific.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TMO insider trading history →

Related articles

OCT 24
$TMOHighAI 8/10

Thermo Fisher Q3 Revenue Hits $12.14 Billion as Shares Touch Record $705 — BigGo Finance

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with shares reaching a record $705.79. Analysts raised target prices. Growth was driven by new products and AI initiatives, including a collaboration with Nvidia. The company also integrated Clario to expand clinical services. Revenue sources include lab consumables (52%) and high-growth areas like mass spectrometry and sequencing. AI and clinical data services are key focus areas for future growth.

finance.biggo.com3 min
OCT 22
$COFHighAI 8/10

Company News for Oct 22, 2026

Capital One (COF) shares rose 2.5% after reporting Q3 2026 adjusted earnings of $6.69 per share, beating estimates. Bank OZK (OZK) shares gained 4.2% with $1.50 per share earnings, surpassing expectations. Thermo Fisher (TMO) shares increased 1% with $6.68 per share earnings, exceeding estimates. Danaher (DHR) shares climbed 4.3% with $2.11 per share earnings, outpacing forecasts.

finance.yahoo.com1 min
OCT 22
$TMOHighAI 8/10

Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth

Thermo Fisher Scientific reported Q3 2026 revenue of $12.14 billion, up 9% YoY, with organic growth of 6%. GAAP EPS rose 9% to $4.64, while adjusted EPS increased 15% to $6.68. The company attributed growth to innovation and strategic initiatives, including new product launches and partnerships. According to CEO Marc Casper, the results reflect strong execution and a proven growth strategy.

biospectrumasia.com2 min